. This unique cell-line bearing the t(15;17) translocation allowed ex vivo studies on APL cells, including the identi®cation of several dierentiation cross talks, as discussed by M Lanotte. That same year, the t(15;17) translocation was cloned and shown to encode a PML/RARa fusion protein, opening the molecular biology era of this disease. The role of RARa in myeloid dierentiation is discussed by P Kastner and that of the various RARa fusion partners in APL pathogenesis by A Zelent and J Licht. Finally, in 1996, Arsenic trioxide (As 2 O 3 ) was shown to be highly eective to induce remissions in untreated and even in ATRA-resistant relapse patients. ATRA therapy restores dierentiation of the leukemic clone. In contrast, the contribution of dierentiation versus apoptosis to disease remission upon As 2 O 3 treatment is still unclear (see article by Z Chen). Remarkably, both ATRA and arsenic target the oncogenic PML/ RARa fusion for activation/degradation, as discussed by H de TheÂ . This issue will attempt to summarize and put in perspective the ®ndings of these last 10 years, which have lead to a surprising amount of discoveries of much broader implication than APL per se.
Paradoxes and pitfalls
Although clinical trials with arsenic or ATRA have been performed in a variety of diseases, only classical APL appears exquisitely sensitive to either of these two agents. The exquisite sensitivity of APL to either agent likely results from their ability to target PML/RARa. It is paradoxical that a genetic alteration in a nuclear hormone receptor (RARa) could confer sensitivity to its cognate hormone (ATRA). Indeed, nuclear receptor defects have been described in a variety of settings, but always associated with hormone resistance. For APL, only pharmacological doses of ATRA bypass the PML/RARa-induced dierentiation block. Hence, APL cells exhibit a relative resistance to physiological doses of ATRA, rather than an exquisite sensitivity to the agent, as proposed by a number of early reviews. PML/RARa targeting by ATRA or arsenic induces the reversal of the APL-speci®c microspeckled distribution of NB-associated proteins into their normal NBpattern. Surprisingly, not all leukemia-associated RARa fusion proteins confer therapeutic sensitivities to ATRA, stressing the importance of the fusion partner. In clinically ATRA-resistant t(11;17)-associated leuke-mia, ATRA-triggered degradation of PLZF/RARa is nevertheless observed. These ®ndings point to complex interactions between oncogene degradation and clinical response and raise the issue of ongoing transformation in the absence of oncogene expression.
Early studies in the NB4 cell-line suggested that arsenic triggers apoptosis and that cell death induction may be the cellular basis of clinical response (see review by Z Chen). At lower concentrations, however, arsenic triggers a signi®cant, but not terminal, dierentiation. Primary APL blasts do not signi®cantly undergo apoptosis upon arsenic treatment ex vivo. Finally, analyses of patients or transgenic mice during arsenic therapy reveal a massive dierentiation. What is the respective contribution of dierentiation versus apoptosis to patients' remission? This bears important implications as to the potential bene®t of co-treatment with the two agents (Gianni et al., 1998; LallemandBreitenbach et al., 1999; Shao et al., 1998) . The list of cellular and viral proteins recruited on PML nuclear bodies (PML NBs) is fast growing. Recruitment appears to be dependent upon modi®cation of PML by SUMO (small ubiquitin modi®er) (Ishov et al., 1999) . Yet, the setting in which this is observed (endogenous proteins versus transfections, analysis of APL cells, several antibodies against the same protein . . .) deserves a special attention. Several reports have pointed to the possibility that PMLs' proapoptotic function may be carried out through NBrecruitment and modulation of Daxx's functions, possibly through a negative control of transcription (Zhong et al., 2000) . Yet, that Daxx induces apoptosis in vivo is far from being established as Daxx knock-out mice show greatly increased apoptosis (Michaelson et al., 1999) . It is commonly accepted that sumolation antagonizes ubiquitin-dependent degradation through competition for conjugation on the same lysine residues (Muller et al., 2001 ). In the case of PML, recent studies suggest that sumolation is required for arsenic-induced PML degradation, questioning how general is sumomediated inhibition of ubiquitin-dependent degradation.
Rediscoveries . . .
Many turning points in the APL ®eld were commonly accepted long after their initial proposal. The simple dominant negative model assuming repression of retinoic acid target genes by the PML/RARa fusion was widely disbelieved in the ®rst place (de TheÂ et al., 1991) . Arti®cial or composite promoters were to blame, because natural genes gave clear-cut results. Yet, with a strong corepressor¯avour (Grignani et al., 1998; Lin et al., 1998) , that disputed proposal became a central dogma, as exposed by R Evans. Similarly, the poor prognosis of bcr3 fusions in ATRA-treated patients, the molecular basis of which remains to be addressed, was accepted long after the initial claims (Vahdat et al., 1994) . The t(15;17) translocation is a balanced one, predicting the existence of a reciprocal fusion protein.
In either t(15;17) or t(11;17) APL, the reciprocal fusions made a striking comeback after the demonstration that they modulate the disease phenotype in mice (He et al., 2000; Pollock et al., 1999) . While this is conceivable for the RARa/PLZF product of the rare variant t(11;17) translocation, that contains a well characterized DNA-binding domain, it is still obscure for the reciprocal RARa/PML fusion that do not bind DNA. Given the central role of PLZF impairment for the development of leukemia in mice (He et al., 2000) , one would expect PLZF target genes to be similarly blocked in PML/RARa triggered malignancies, which could shed a new light on the proposed inter-relations between PML and PLZF. This is just an example of how the power of mouse genetics has allowed an unprecedented analysis in vivo of both leukemogenesis and yielded the ®rst mouse preclinical trials of leukemia (Lallemand-Breitenbach et al., 1999) (see article by PP Pandol®).
What about the celebrated PML nuclear bodies that pop up in so many dierent ®elds of biology, new or rediscovered' organelles, as a 1992 review already pointed out (Brasch and Ochs, 1992) . These organelles have been shown to be organized by sumolated PML and are alternatively denominated nuclear bodies (NBs), nuclear dot 10 (ND10) or PML oncogenic domains (PODs) of Kr (for kruÈ ppell) bodies. POD is inappropriate since these organelles appear to be associated with anti-oncogenic functions. Kr bodies or ND10 are historical names that do not take into account the role of PML to organize this domain. As the name of the original NBs discoverers in 1960 (de TheÂ et al., 1960) , de TheÂ /Bernhardt bodies is unlikely to reach a consensus among the PML community, we propose to refer to these organelles as PML NBs, a proposal accepted by most of our colleagues. PML isoforms were a cloners' nightmare of exon shuing to which very few paid any attention, despite a very careful initial description (Fagioli et al., 1992) . For years, PML indistinctly designated distinct proteins. These PML isoforms could make distinct interactions (leading to distinct functions), yielding at last a strong need for a common nomenclature (see review by P Freemont). Use of distinct isoforms could account for some of the contradictions in the literature.
Opened questions
If forced dimerization of RARa suce to block myeloid dierentiation, why is PML rearranged in over 95% APL cases? Conversely, the RAR family comprises three members a b g, whose DNA-binding speci®city is virtually identical. Why fusions involving RARb or RARg were never observed? PML/RARa is a transcriptional repressor whose target genes are largely unknown. How many PML/RARa targets exist in APL cells? How many of these targets are critical for either the dierentiation block or the response to ATRA or possibly to arsenic? Opinions vary widely, from a handful of critical genes to a whole set. Are all these RARa target genes? Nuclear receptor target genes? Or are some PML/RARa target genes only? This last possibility would constitute a dominant gain of function of the fusion. In NB4 cells, ATRA treatment induces the massive synthesis of interferon a (Pelicano et al., 1999) . Among ATRA target genes identi®ed, many are in fact interferon-induced. These gene products are unlikely to be implicated in the maturation process, as interferon a does not trigger APL cell dierentiation. The demonstration of a parallel dierentiation pathway by speci®c RXR analogues combined to cAMP awaits a molecular explanation (Benoit et al., 1999) .
PML was recently proposed to trigger senescence (reviewed by Gottifredi and Prives, 2001) . This is particularly interesting because PML expression is very high at the early stage of a wide variety of human tumours (Koken et al., 1995; Terris et al., 1995) . There is some connection between alternative telomerase activity, DNA repair and PML NBs. Recently several groups found that PML-induced senescence requires a functional p53 pathway, but how PML triggers senescence is still unclear (see chapter by PG Pelicci). The function of PML NBs is largely unknown. These represent highly dynamic structures with a growing number of proteins recruited to these domains depending on the setting (viral infection, transformation, IFN-treatment). This plethora of NB-associated proteins is worrisome. Can PML NBs really be implicated in modulating the function of each of them? In that sense, PML was proposed to play a key role in everything from transcriptional control, genome stability, cell-cycle control, apoptosis senescence, IFN response. Protein degradation, which was suggested, but never demonstrated, could reconcile many of these ®ndings. PML shuttles between the nucleoplasm and nuclear matrix-associated NBs. Where are the function(s)? in the nucleoplasm, in NBs or in both compartments? Or could it be the tracking itself that is key to the function. In that case, sumolation which controls NBs-formation, would play a key role in PML-NBs function, as discussed by A Dejean. In turn, then, what controls PML sumolation? Phosphorylation is an obvious candidate, but the upstream pathways are unidenti®ed. Viruses may again provide some clues to these issues. Recurrent alterations within NBs are found following expression of immediate early genes of many DNA viruses as reviewed by R Everett with a special emphasis on HSV-1. PML is interferon-induced and some data suggest that this protein could be a mediator of the antiviral activities of IFN (Regad et al., 2001) . The disorganization of PML NBs may be part of the general viral strategy to counteract interferon action (see review by M Chelbi-Alix).
Lessons from the APL story APL and PML/RARa driven oncogenesis illustrates well the role of deregulated transcription in oncogenesis. Many transcription factors become oncogenes when they acquire a modi®ed activity or an ectopic expression. What makes the APL example unique is that deregulated transcription can be manipulated through a variety of strategies (ligand-dependent activation, histone deacetylation, PKA activation) and that this reprogramming lead to dierentiation and ultimately disease remission, yielding the concept of transcriptional therapy. The contribution of animal models to the dissection of APL pathogenesis and their sensitivity to ATRA and arsenic in clinical trials, opens a new era of drug testing in genetically modi®ed animals. This could promote the identi®cation of new therapies in ATRA-resistant t(11;17) leukemias. The APL model has also stressed the role of protein catabolism in therapeutic response. It is likely that the advances made in the ®eld of proteolysis will unravel many more connections with oncogenesis. By linking PML NBs reorganization to both leukemogenesis and therapeutic response, the APL story has also shed an unexpected light on the relationship between an altered nuclear organization and pathogenic processes. Indeed, PML NBs are disrupted in viral infections or other diseases such as polyglutaminassociated neuro-degeneration. Moreover, nuclear domains other than PML NBs were found to be disorganized in a variety of genetic diseases, stressing the importance of nuclear structure for its functions. It is likely that transcription and proteolysis control or nuclear organization will have new implications in oncogenesis or therapeutic interventions. Ecient inhibitors of the bcr-abl kinase have recently made their way to the clinic, con®rming how the concept of oncogene targeted therapies, with little toxicity and high eciencies, is the likely future of cancer drugs.
Abbreviations PML, promyelocytic leukemia; APL, acute promyelocytic leukemia; NBs, nuclear bodies; ATRA, all trans retinoic acid; As 2 O 3 , arsenic trioxide; PLZF, promyelocytic zinc ®nger; RAR, retinoic acid receptor; IFN, interferon; SUMO, small ubiquitin modi®er.
